Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
GE Healthcare will become a standalone company, distinct from GE, as the conglomerate focuses on its aviation, power, and renewable energy businesses, the company announced June 26. Current GE Healthcare CEO Kieran Murphy will continue to lead the business, which will maintain the GE Healthcare brand. GE plans to monetize 20% and distribute the remaining 80% of GE Healthcare to shareholders tax-free.
Latest From Companies
Biodesix Inc. is acquiring Integrated Diagnostics Inc. for both its flagship XL2 lung-cancer test and to upgrade its ability to develop new pharma companion diagnostics. See what Biodesix CEO David Brunel said about it here.
Biodesix has acquired Integrated Diagnostics for an undisclosed sum to add the XL2 lung-cancer test to its molecular diagnostics line-up and to acquire technology and expertise that can improve its biopharma business.
As US FDA has been on a quest to encourage gathering more real-world data, companies like Medtronic and Johnson & Johnson seem to be hopping on the bandwagon with partnerships to gather and analyze how their products really perform.
Medtech M&A activity waned in June, with the market showing signs of a summer slump. Twelve acquisitions were announced and closed during the month, a dip in activity compared to the 21 deals recorded in the same period last year, and the 17 recorded in May.
The US Defense Logistics Agency, which supports troops across the military, has awarded a $471.6m contract for cardiovascular products to Medtronic.
Having acquired Alcon for an eye-watering $52bn seven years ago, the Swiss major has decided that spinning off the eyecare business which has finally returned to growth (but is worth about half what Novartis paid in 2011) makes the most sense as it becomes a company even more focused on pharma.
Swiss Advanced Vision is extending its expertise in intraocular lenses to develop a new line of smart IOLs that automatically focus in real-time to correct presbyopia. These active lenses will also have a remote calibration feature so they can easily be adjusted post-implantation.
Clinical diagnostics firm Novacyt's M&A growth strategy is underway with the company announcing a bargain deal to buy the infectious disease business of Omega Diagnostics.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.